Zacks Investment Research downgraded Accelerate Diagnostics Inc (NASDAQ:AXDX) to Sell in a report released today.
- Updated: September 27, 2016
Zacks Investment Research has downgraded Accelerate Diagnostics Inc (NASDAQ:AXDX) to Sell in a report released on 9/27/2016.
Yesterday Accelerate Diagnostics Inc (NASDAQ:AXDX) traded 0.63% higher at $27.18. The company’s 50-day moving average is $23.76 and its 200-day moving average is $17.03. The last closing price is up 59.59% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 163,301 shares of the stock were exchanged, down from an average trading volume of 347,094
See Chart Below
Accelerate Diagnostics Inc has a 52 week low of $10.29 and a 52 week high of $28.50 The company’s market cap is currently $0.
In addition to Zacks Investment Research reporting its target price, a total of 2 brokers have issued a report on the stock. The consensus target price is $25.50 with 2 brokers rating the stock a strong buy, 1 broker rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.
General Information About Accelerate Diagnostics Inc (NASDAQ:AXDX)
Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The Company's technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types. The Company is focused on the development of a rapid diagnostic platform, the Accelerate ID/AST System (ID/AST System or Accelerate ID/AST System), intended for the diagnosis of infectious pathogens. The ID/AST System utilizes genotypic technology to identify (ID) infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. The ID/AST System features walk-away automation and consists of a fixed instrument and single-use test kit.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.